Related by context. All words. (Click for frequent words.) 70 Pancreatic Cancer 69 Myeloma 68 Chronic Lymphocytic Leukemia 68 Bladder Cancer 65 Non Hodgkin Lymphoma 64 Myelodysplastic Syndromes 64 Mantle Cell Lymphoma 64 Lung Cancer 64 Pulmonary Hypertension 63 Chronic Myeloid Leukemia 63 Lymphoma 63 Neck Cancer 63 Multiple Sclerosis 63 Liver Cancer 63 multiple myeloma 63 Renal Cell Carcinoma 62 Myelodysplastic Syndrome 62 Thyroid Cancer 61 Acute Myeloid Leukemia 61 Prostate Cancer 61 Rheumatoid Arthritis 61 Gastric Cancer 61 Cell Lung Cancer 61 Acute Lymphoblastic Leukemia 61 Autoimmune Diseases 60 Autoimmune Disease 60 Cancer 60 Colorectal Cancer 60 Malignant Melanoma 60 Colon Cancer 60 Metastatic Breast Cancer 60 Acute Myelogenous Leukemia 60 Glioblastoma Multiforme 60 Breast Cancer 59 Advanced Melanoma 59 Scleroderma 59 Pulmonary Fibrosis 59 Hodgkin Lymphoma 59 Esophageal Cancer 59 Cell Lymphoma 59 Metastatic Colorectal Cancer 59 Myelofibrosis 59 Sarcoma 59 Stomach Cancer 59 Friedreich Ataxia 59 Cutaneous T 59 Ovarian Cancer 58 Hematological Malignancies 58 Renal Cancer 58 Chronic Lymphocytic Leukemia CLL 58 Solid Tumors 58 Acute Leukemia 58 Carcinoma 58 HER2 positive breast cancer 58 Cystic Fibrosis 58 Cell Transplant 58 Inflammatory Bowel Disease 58 Neuroendocrine 58 Metastatic Melanoma 58 Breast Cancer Treatment 57 Batten Disease 57 Crohn Disease 57 Advanced Renal Cell 57 NSCLC 57 Pancreatic 57 Gastrointestinal Oncology 57 chronic lymphocytic leukemia 57 Hormone Refractory Prostate Cancer 57 Newly Diagnosed Multiple Myeloma 57 Leukemia Lymphoma 57 Blood Cancers 57 Multiple Myeloma Patients 57 Inflammatory Breast Cancer 57 Liver Disease 57 Huntington Disease 57 Ulcerative Colitis 57 Borderline Personality Disorder 57 T Cell Lymphoma 57 Lung Cancer Patients 57 Rectal Cancer 57 Newly Diagnosed 56 Advanced Prostate Cancer 56 Acute Heart Failure 56 Metastatic Cancer 56 Malignant Mesothelioma 56 Relapsed Refractory Aggressive 56 Brain Tumor 56 Kidney Disease 56 Ovarian Cancer Patients 56 metastatic colon cancer 56 Cancer Immunotherapy 56 Anthracycline 56 metastatic breast cancer 56 Stem Cell Transplant 56 Chronic Myelogenous Leukemia 56 Glioblastoma 56 Previously Treated 56 Anticancer Drug 56 Clinical Trial Results 56 Leukemias 56 Investigational Drug 56 Hepatocellular Carcinoma 56 metastatic melanoma 56 Metastatic Prostate Cancer 56 Soft Tissue Sarcoma 56 Gynecological Cancer 56 Leukemia 56 Follicular Lymphoma 56 Alzheimer Disease 56 RNAi Therapeutic 55 HER2 Positive Breast Cancer 55 Relapsed Refractory 55 Chronic Hepatitis C 55 Bipolar Disorder 55 Hematologic Malignancies 55 Breast Cancer Patients 55 Prostate Cancer Treatment 55 Subgroup Analysis 55 Colorectal 55 Metastatic 55 ASCO GI 55 Unresectable 55 cancer 55 Survival Benefit 55 Pulmonary Arterial Hypertension 55 Previously Untreated 55 Acute Myeloid Leukemia AML 55 Brentuximab Vedotin SGN 55 Advanced Colorectal Cancer 55 myeloma 55 ovarian cancer 55 Dose Escalation Study 55 Carcinoid 55 metastatic colorectal cancer 55 relapsed multiple myeloma 55 Testicular Cancer 55 Antitumor Activity 55 Insulin Resistance 55 Overactive Bladder 55 Melanoma 55 Pleural Mesothelioma 55 Endometrial Cancer 55 chronic lymphocytic leukemia CLL 55 Malignant Brain Tumor 55 HER2 positive metastatic breast 54 Cholangiocarcinoma 54 Bipolar Disorders 54 Idiopathic Pulmonary Fibrosis 54 Childhood Leukemia 54 metastatic cancer 54 Novel Oral 54 Systemic Sclerosis 54 Breast Cancer Recurrence 54 Lupus Nephritis 54 Severe Sepsis 54 Emerging Therapies 54 Neoadjuvant 54 Relapsing Multiple Sclerosis 54 Novel Therapies 54 metastatic prostate cancer 54 Gaucher Disease 54 GIST 54 relapsed leukemia 54 Glioma 54 Diffuse Large B 54 Cancer Therapy 54 Targeted Therapy 54 Prolongs Survival 54 Autoimmune 54 Non Hodgkins Lymphoma 54 Movement Disorder 54 HER2 Positive 54 Biological Therapy 54 pancreatic cancer 54 Lung Cancers 54 Kidney Cancer 54 Vasculitis 54 Randomized Phase II 54 Polycystic Kidney Disease 54 colorectal cancer 54 Hematology Meeting 54 Heart Failure 54 B Cell Lymphoma 54 Kinase Inhibitors 54 Multiple Myeloma MM 54 Amyotrophic Lateral Sclerosis ALS 54 Anticancer Drugs 54 Castration Resistant Prostate Cancer 54 Anti Tumor 54 Abstract # 54 Neuroendocrine Tumor 54 Solid Tumor 54 Targeted Therapies 54 Bipolar Depression 53 Mitochondrial Disease 53 Adjuvant Therapy 53 Metastatic Renal Cell Carcinoma 53 Diabetic Patients 53 Sipuleucel T 53 Prostate Cancer Patients 53 Breast Cancers 53 Abiraterone Acetate 53 sarcoma 53 Lupus 53 Parkinson Disease 53 Cancer Treatment 53 Inflammatory Disease 53 Acute Ischemic Stroke 53 Juvenile Arthritis 53 leukemia CLL 53 pancreatic adenocarcinoma 53 Liver Diseases 53 Myelodysplastic Syndrome MDS 53 lymphoma 53 Phase III Trial 53 Kinase Inhibitor 53 Therapeutic Potential 53 Adjuvant Chemotherapy 53 prostate cancer mCRPC 53 prostate cancer HRPC 53 Genetic Variation 53 Cancer Therapies 53 glioblastoma 53 Tyrosine Kinase Inhibitor 53 Acute Myelogenous Leukemia AML 53 Oral Fingolimod 53 Interstitial Cystitis 53 multiple myeloma MM 53 relapsing multiple sclerosis 53 differentiated thyroid 53 Orphan Diseases 53 Stem Cell Transplants 53 Oral Mucositis 53 Duchenne Muscular Dystrophy 53 Cystinosis 53 Preclinical Models 53 Predict Response 53 Postmenopausal Women 53 melanoma 53 Neuropathic Pain 53 advanced NSCLC 53 Li Fraumeni Syndrome 53 Medical Oncology 53 non Hodgkin lymphoma 53 malignant pleural mesothelioma 53 Mouse Model 53 Improved Survival 53 Anticancer Activity 53 Gastrointestinal Cancer 53 Epidermal Growth Factor Receptor 53 Hormone Receptor Positive 53 Newly Diagnosed Patients 53 gastrointestinal stromal tumors 53 Epratuzumab 53 Neoplasia 53 castration resistant prostate cancer 53 Treatment Resistant 53 Genes Predict 53 Hsp# Inhibitor 53 Localized Prostate Cancer 52 SABCS 52 Predict Breast Cancer 52 ALS Amyotrophic Lateral Sclerosis 52 lupus 52 Waldenstrom Macroglobulinemia 52 breast cancer 52 Clinical Oncology 52 prostate cancer CRPC 52 Prostrate Cancer 52 lymphoma CTCL 52 Brain Tumors 52 Philadelphia Chromosome Positive 52 gastrointestinal stromal tumor GIST 52 Chronic lymphocytic leukemia 52 Congestive Heart Failure 52 Lung Cancer Survival 52 Prenatal Diagnosis 52 Adenoid Cystic Carcinoma 52 acute myeloid 52 Autoimmune Disorders 52 Acute Renal Failure 52 Improves Outcomes 52 Romidepsin 52 Advanced Ovarian Cancer 52 Gemcitabine 52 Cell Non Hodgkin 52 Aggressive Prostate Cancer 52 Systemic Lupus Erythematosus SLE 52 Adjuvant Treatment 52 Breast Cancer Survival 52 Psychiatric Disorders 52 Randomized Phase 52 Inflammatory Diseases 52 Ewing Sarcoma 52 Study Evaluating 52 Chronic Fatigue Syndrome 52 Hepatocellular 52 Rheumatoid Arthritis Patients 52 Colorectal Cancer Screening 52 Diabetic Nephropathy 52 neuroendocrine tumors 52 Neovascular Age Related Macular 52 Acute Stroke 52 carcinoid cancer 52 Heart Failure Patients 52 Bevacizumab 52 Decitabine 52 Neoadjuvant Chemotherapy 52 Neurodegenerative Disorders 52 Wilm Tumor 52 Lung Cancer Drug 52 Cancers Symposium 52 IL# PE#QQR 52 Autoimmunity 52 Malignant Glioma 52 Preclinical Study 52 leukemia AML 52 histone deacetylase HDAC inhibitor 52 Acute Promyelocytic Leukemia 52 Advaxis Phase 52 metastatic renal cell carcinoma 52 leukemia ALL 52 renal cell carcinoma 52 Adjuvant Breast Cancer 52 Complicated Skin 52 Myelodysplastic Syndromes MDS 52 cancer mCRC 52 Squamous Cell Carcinoma 52 Antiangiogenic 52 mCRC 52 Eculizumab 52 metastatic gastric 52 Cardiovascular Outcomes 52 Safinamide 52 recurrent glioblastoma multiforme 52 Bronchiectasis 52 Pooled Analysis 52 Meets Primary Endpoint 52 Improves Survival 52 Phase 2b Clinical Trial 52 HDAC Inhibitor 52 Neuroblastoma 52 Breast Cancer Diagnosis 52 Immunodeficiencies 52 Monoclonal Antibody 52 Acute myeloid leukemia 52 Chronic Illness 52 Neuro Oncology 52 Macular Degeneration 52 Colorectal Cancer Patients 52 Neurodegenerative Disease 52 Parkinson Disease PD 52 Bone Marrow Transplantation 51 atypical Hemolytic Uremic Syndrome 51 gastric cancer 51 Improve Survival 51 unresectable stage 51 ISTODAX ® 51 Hereditary Angioedema 51 pancreatic islet cell 51 II Clinical Trial 51 Severe Asthma 51 Immunotherapeutic 51 Randomized Phase III 51 Patients Treated With 51 Hodgkin lymphoma HL 51 Allergic Rhinitis 51 Cancer Diagnosis 51 Non Hodgkin 51 Kidney Transplant Patients 51 Hematology 51 cell lymphoma CTCL 51 ThermoDox R 51 IgG1 monoclonal antibody 51 Hematological Cancers 51 gastrointestinal stromal tumor 51 Liver Metastases 51 Randomized Study 51 Relapsed Refractory Multiple Myeloma 51 Invasive Breast Cancer 51 Malignancy 51 Cancer EORTC 51 Preclinical Studies 51 Osteosarcoma 51 Vulnerable Plaque 51 Bone Marrow Transplant 51 Bortezomib 51 ALS 51 Drug Shows Promise 51 Waldenstrom macroglobulinemia 51 Colorectal Cancer CRC 51 Chronic Pelvic Pain 51 Cancer Patients Treated 51 antibody MAb 51 Alzheimers Disease 51 Diagnostic Criteria 51 acute myeloid leukemia 51 Anticancer 51 Ankylosing Spondylitis 51 Metastatic breast cancer 51 Spinal Muscular Atrophy 51 Peritoneal Mesothelioma 51 Thyroid Disease 51 Paroxysmal Nocturnal Hemoglobinuria PNH 51 Cancer AACR NCI 51 Neuroendocrine Tumors 51 Trigeminal Neuralgia 51 RNAi Therapeutics 51 Hodgkin Disease 51 Diabetic Macular Edema 51 Gene Mutation 51 Toxicogenomics 51 Clinical Oncology Annual Meeting 51 PKC# 51 Breast Tumors 51 Rheumatoid Arthritis RA 51 Biomarker Discovery 51 Investigational Agent 51 Autologous Stem Cell Transplantation 51 Renal Cell Cancer 51 Supportive Care 51 Oxidative Stress 51 non squamous 51 Anti Angiogenesis 51 Aflibercept 51 recurrent NSCLC 51 colon cancer 51 Omacetaxine 51 Pegylated Interferon 51 B Cell Malignancies 51 T#I [002] 51 Peripheral Artery Disease 51 metastatic castration resistant 51 Node Positive 51 Novel Therapeutic 51 Breast Cancer Metastasis 51 Hematologic 51 Novel Treatments 51 Breast Cancer Cells 51 Cancer Vaccines 51 Aplastic Anemia 51 Schizophrenia 51 Monoclonal Antibodies 51 Ischemic 51 Bayer Nexavar 51 Brain Aneurysm 51 Juvenile Rheumatoid Arthritis 51 Alemtuzumab 51 Hemodialysis Patients 51 Acute Myocardial Infarction 51 Daniel Von Hoff 51 Relapsed 51 Vandetanib 51 soft tissue sarcoma 51 Systemic Lupus Erythematosus 51 Acute Myeloid Leukaemia AML 51 Gastrointestinal Stromal Tumors 51 Gefitinib 51 Hepatitis C Virus 51 Natalizumab 51 Patients Treated 51 Clinical Outcome 51 Low Dose 51 Movement Disorders 51 Treating Chronic 51 Lymphomas 51 Progenitor Cells 51 Adenoma 51 Minimally Invasive Treatment 51 Vascular Targeting Agents 51 Anaplastic 51 Enlarged Prostate 51 solid tumors 51 Anti Tumor Activity 51 Atypical Hemolytic Uremic Syndrome 51 Postmenopausal Osteoporosis 51 Peginterferon 51 prostate cancer 51 Investigational Treatment 51 inoperable pancreatic cancer 51 Angiogenesis 51 Cardiac Arrhythmias 50 Novel Approaches 50 Preclinical Data 50 Tyrosine Kinase Inhibitors 50 paroxysmal nocturnal hemoglobinuria PNH 50 Pralatrexate 50 PEGylated interferon beta 1a 50 Immune Mediated 50 Thrombotic 50 Human Neural Stem 50 Nicotine Vaccine 50 Metastatic Pancreatic Cancer 50 Frontotemporal Dementia 50 Relapsing Remitting Multiple Sclerosis 50 Fibrosis 50 Cancer Stem Cells 50 Phase III Trials 50 Biomarker 50 Crohn 50 Atrial Fibrillation 50 Chicago Multidisciplinary Symposium 50 Metastases 50 UM Comprehensive Cancer 50 ErbB2 positive 50 Hepatocellular Carcinoma HCC 50 Dendritic Cells 50 Cyclophosphamide 50 Ischemic Stroke 50 Chronic Leukemia 50 Investigational Compound 50 Antiviral Activity 50 Presents Preclinical Data 50 Vitro Activity 50 pleural mesothelioma 50 Acute Coronary Syndromes 50 recurrent glioma 50 Mood Disorders 50 Demonstrates Potent 50 neuroblastoma 50 Multicenter Study 50 Long Term Efficacy 50 stage IIIb 50 Prostate 50 Relapsed Multiple Myeloma 50 PXD# 50 leukemia myeloma 50 Dacogen injection 50 Inflammatory Markers 50 Coronary Heart Disease 50 Malignancies 50 Cell Therapy 50 Drug Candidate 50 pancreatic neuroendocrine tumors 50 metastatic colorectal 50 Sclerosis 50 Acute Pancreatitis 50 Liver Transplantation 50 myelofibrosis 50 Chronic Myeloid Leukemia CML 50 Psoriasis Patients 50 Antiviral Therapy 50 advanced hepatocellular carcinoma 50 Phase III Clinical Trial 50 CYT# potent vascular disrupting 50 carfilzomib 50 Leber Hereditary Optic Neuropathy 50 HCV Protease Inhibitor 50 Hematology Annual Meeting 50 ECTRIMS 50 cetuximab Erbitux 50 Combination REOLYSIN R 50 Cognitive Impairment 50 Peripheral Arterial Disease 50 Medical Oncology ESMO 50 Inflammatory Bowel Diseases 50 Prostate Cancers 50 Hedgehog Pathway Inhibitor 50 Pemetrexed 50 pertuzumab 50 Cachexia 50 Glufosfamide 50 ZACTIMA 50 Antitumor activity 50 Breast Cancer Detection 50 Chronic Heart Failure 50 Combination Therapy 50 lung cancer 50 Phase IIb Trial 50 Prognostic Factors 50 Cancer Therapeutic 50 Multicenter Phase 50 Short Stature 50 Genetic Testing 50 Neural Stem Cells 50 Cardiotoxicity 50 Metabolic Disease 50 Lung Cancer Treatment 50 Thoracic Oncology 50 Patients Receiving 50 Oral Formulation 50 gastrointestinal stromal tumors GIST 50 Therapy Evaluation 50 Urinary Incontinence 50 Anti TNF 50 Pivotal Study 50 erlotinib Tarceva ® 50 Demonstrates Potential 50 neratinib 50 Pancreatic Adenocarcinoma 50 Neurodegenerative 50 Erectile Dysfunction Drug 50 Neuroprotection 50 Migraine Headache 50 Amrubicin 50 hematologic malignancies 50 Therapeutic Antibody 50 Complete Remission 50 Respiratory Virus 50 Heart Disease 50 HuMax EGFr 50 Carcinoid Syndrome 50 Improve Outcomes 50 IV NSCLC 50 pediatric sarcoma 50 non hodgkin lymphoma 50 gefitinib Iressa 50 metastatic renal cell 50 Juvenile Idiopathic Arthritis 50 Neoplasms 50 Chronic Hepatitis B 50 Chronic Sinusitis 50 systemic lupus erythematosus 50 hepatocellular cancer 50 Disease Progression 50 Treatment Naive Patients 50 Eye Diseases 50 Phase 2a Clinical Trial 50 Irinotecan 50 Lymphoma Patients 50 Chronic Pain 50 Meta Analysis 50 DIPG 50 Radiation Treatment 50 Leber Congenital Amaurosis LCA 50 Sjogren Syndrome 50 JAK Inhibitor 50 Novel Mechanism 50 nonsmall cell lung cancer 50 Cancer Treatments 50 Dose Escalation 50 Hepatic Encephalopathy 50 Small Molecule 50 Tesetaxel 50 Perifosine 50 Lung Cancer Trial 50 Venous Thrombosis 50 SUTENT ® 50 Kidney Failure 50 Slow Progression 50 Monotherapy 50 Elotuzumab 50 Sustained Reduction 50 Liver Tumors 50 enzastaurin 50 Advanced Solid Tumors 50 Postpartum Depression 50 Coronary Artery Disease 50 Recurrent Ovarian Cancer 50 Novel Anticancer 50 Hematological 49 Novel Therapeutics 49 Atiprimod 49 vandetanib 49 Newly Diagnosed Breast Cancer 49 Cardiometabolic 49 Female Sexual Arousal 49 Analytical Tool 49 Patient Outcomes 49 Cloretazine ® 49 sunitinib 49 Gynecological Cancers 49 Bone Metastases 49 Jonsson Comprehensive Cancer 49 Personality Disorders 49 bone metastases 49 PROSTATE CANCER 49 Receives Positive Opinion 49 Breast Cancer Risk 49 Psoriasis 49 Randomized Double blind 49 Squamous 49 Oncology 49 chronic myeloid leukemia CML 49 Protein Involved 49 Taxotere ® 49 Diagnosis Treatment 49 LUX Lung 49 Chronic Kidney Disease 49 Prostate Cancer Survival 49 neuroendocrine cancer 49 aflibercept 49 Advanced Heart Failure 49 Hospital Acquired Pneumonia 49 Neulasta ® 49 Zarnestra 49 Peripheral Neuropathy 49 Genetic Disorder 49 Golimumab 49 Clinical Efficacy 49 familial amyloidotic polyneuropathy FAP 49 acute PAO 49 Risk Stratification 49 Naive Patients 49 gastrointestinal malignancies 49 Prospective Randomized 49 acute myelogenous leukemia AML 49 Islet Transplantation 49 chronic granulomatous disease 49 Molecular Origins 49 Platelet Inhibition 49 acute myelogenous 49 Present Preclinical Data 49 metastatic GIST 49 Hemorrhagic Stroke 49 Genitourinary Cancers Symposium 49 5 Fluorouracil 49 Wilms Tumor 49 follicular lymphoma 49 idiopathic pulmonary fibrosis IPF 49 ZACTIMA TM ZD# 49 Therapeutic Targets 49 Placebo Controlled Study 49 RNA Interference 49 Statistically Significant 49 CLL 49 Enzyme Replacement Therapy 49 Capecitabine 49 hormone refractory prostate cancer 49 Growth Hormone Deficiency 49 Oral Cancer 49 non Hodgkin Lymphoma 49 Oral Presentations 49 essential thrombocythemia ET 49 Trial Evaluating 49 Crohn disease 49 Acute Lymphoblastic Leukaemia 49 Pivotal Phase 49 Aurora Kinase 49 angiogenesis inhibition 49 Burkitt Lymphoma 49 relapsed ovarian cancer 49 Molecular Biomarkers 49 gastrointestinal cancers 49 sunitinib Sutent 49 Mitochondrial Dysfunction 49 Advanced Pancreatic Cancer 49 LHON 49 nab paclitaxel 49 TACI Ig 49 relapsed refractory multiple myeloma 49 APPRAISE 49 Anti Angiogenic 49 NSABP 49 Cancer Biomarkers 49 Psoriatic Arthritis 49 Hormone Receptor 49 Trastuzumab 49 Cardiovascular Diseases 49 demonstrated antitumor activity 49 Autism Spectrum Disorders 49 Genetic Disorders 49 Pertuzumab 49 Renal Anemia 49 cholangiocarcinoma 49 AA Amyloidosis 49 Anal Cancer 49 Anthrax Toxin 49 HRPC 49 IRESSA 49 Carotid Stenting 49 Sustained Efficacy 49 Chemotherapeutic Agents 49 chronic myelogenous leukemia 49 Placebo Controlled Trial 49 haematologic malignancies 49 Prognostic Significance 49 Esophageal 49 Marrow Transplant 49 Bipolar Mania 49 Fixed Dose 49 AACR IASLC Joint 49 Rituximab 49 Throat Cancer 49 Critical Limb Ischemia 49 Cancer Recurrence 49 Apaziquone 49 Doxil ® 49 Stent Thrombosis 49 Inhaled Liposomal Ciprofloxacin 49 RCW Breast Cancer 49 myelofibrosis polycythemia vera 49 Myeloma Patients 49 bone metastasis 49 Migraine Pain 49 myelodysplastic syndromes 49 huN# DM1 49 Basal Cell Carcinoma 49 Neck Cancers 49 Completes Patient Enrollment 49 Therapeutic Antibodies 49 myelodysplastic syndrome 49 Developmental Therapeutics 49 FOLOTYN ® 49 Gastrointestinal Cancers 49 Ofatumumab 49 Multicenter Trial 49 cilengitide 49 Pediatric Brain Tumors 49 Cell Transplants 49 Phase 2b Trial 49 Etanercept 49 Smooth Muscle 49 Aryplase 49 Septic Shock 49 Childhood Cancer 49 Cardiac Stem Cell 49 perifosine 49 Ewing sarcoma 49 Chronic Rhinosinusitis 49 Fludarabine 49 Metabolic Disorders 49 bladder cancer 49 Liver Failure 49 Fluorouracil 49 leukemia 49 Laryngeal Cancer 49 PEG SN# 49 panitumumab Vectibix 49 Primary Biliary Cirrhosis 49 leukemia lymphoma 49 Herceptin trastuzumab 49 pediatric malignancies 49 hormone refractory metastatic prostate 49 Randomized Double Blind Placebo 49 Alzheimer Dementia 49 Randomized Controlled 49 Radiation Therapy 49 JAK2 Inhibitor 49 Well Tolerated 49 Chemotherapy 49 Fulvestrant 49 complement inhibitor eculizumab 49 Tumor Markers 49 Antiplatelet Therapy 49 Colorectal Adenomas 49 Urologic Cancer 49 Bosutinib 49 Treatment Options 49 ependymoma 49 Interferon Alfa 49 EORTC 49 Elderly Patients 49 Venous Thromboembolism 49 Iron Overload 49 Breaking Clinical Trials 49 Factor Receptor 49 Benign Prostatic Hyperplasia 49 Scleroderma Research 49 Evoltra ® 49 Adenomas 49 Major Depressive Disorder 49 galiximab 49 Poster Discussion 49 Chemotherapy Improves 49 Controlled Trial 49 lymphoblastic leukemia 49 tyrosine kinase inhibitors TKIs 49 metastatic hormone refractory 49 Cancers 49 stage IIIB 49 Drug Discovery 49 cetuximab 49 BCIRG 49 Long Term Survival 49 Diabetic Retinopathy 49 Breast Oncology 49 Progressive Multifocal Leukoencephalopathy 49 MPS VI 49 Plus Ribavirin 49 Synovial Sarcoma 49 Sapacitabine 49 Kidney Stones 49 Gene Linked 49 Novel Antibiotic 49 EGFR HER2 49 Dupuytren Contracture 49 Therapy Improves 49 CT Angiography 49 Rhabdomyosarcoma 49 Pivotal Phase III 49 Surgical Treatment 48 brain tumor glioblastoma multiforme 48 Camptosar ® irinotecan 48 Initiate Phase 48 myeloproliferative disorders 48 Biomarker Study 48 Metastatic Colon Cancer 48 Breast Disease 48 breast carcinoma 48 recurrent ovarian cancer 48 Coronary Artery 48 Chronic Fatigue 48 pan HDAC inhibitor 48 Childhood Brain Tumor 48 Migraine Headaches 48 CRLX# 48 Prognostic Value 48 Knee Osteoarthritis 48 hematological malignancies 48 Prostate Cancer Risk 48 nasopharyngeal carcinoma 48 imatinib Gleevec ® 48 Cetuximab 48 advanced metastatic renal 48 Gene Variant 48 Neuro Oncology SNO 48 Trastuzumab DM1 48 plus prednisone 48 Receives Orphan Drug Designation 48 Vectibix 48 acute leukemia 48 Basal Cell 48 Infantile Spasms 48 Hodgkin lymphoma 48 Pancreas Cancer 48 Atopic Dermatitis 48 SPRYCEL ® 48 ALS Lou Gehrig 48 KRN# 48 Molecular Therapy 48 Vascular Disease 48 KRAS mutation 48 Study Showed 48 glioblastoma multiforme GBM 48 Kidney Transplant Recipients 48 Phase IIa Clinical Trial 48 Diabetes Complications 48 Adenocarcinoma 48 BIBW 48 Refractory Angina 48 Nexavar ® 48 Hematology ASH Annual Meeting 48 Clofarabine 48 Pixantrone 48 Hodgkins Disease 48 CTCL 48 Romiplostim 48 Therapeutic Vaccines 48 chemotherapy FOLFOX 48 Alzheimer Disease AD 48 Virus Infection 48 Pirfenidone 48 Myocardial Ischemia 48 Thromboembolism 48 Selective Internal 48 Nonalcoholic Fatty Liver Disease 48 Clinical Cancer 48 Circulating Tumor Cells 48 Orally Active 48 Late Breaker 48 Successfully Completes Phase 48 Generalized Anxiety Disorder 48 Triapine 48 Imprime PGG 48 essential thrombocythemia 48 Prostate Biopsy 48 abiraterone acetate 48 relapsing remitting multiple sclerosis 48 Squamous Cell 48 Myocardial Infarction 48 Alzheimer 48 Treatment Naive 48 Non Hodgkins lymphoma 48 ASH Annual Meeting 48 Maroteaux Lamy syndrome 48 vinca alkaloid 48 panobinostat 48 squamous cell cancer 48 Orphan Drug 48 Brain Metastases 48 Etiology 48 ® cetuximab 48 unresectable Stage III 48 dasatinib 48 Fibromyalgia Syndrome 48 Myelodysplasia 48 Proves Effective 48 Antibody Drug Conjugate 48 ST Elevation Myocardial 48 lymphocytic leukemia 48 Hypercholesterolemia 48 Meningiomas 48 ST Segment Elevation 48 Recurrent Prostate Cancer 48 diabetic nephropathy 48 AACR San Antonio 48 Observational Study 48 Temodar ® 48 Thyroid 48 Nilotinib 48 myelodysplastic syndrome MDS 48 Therapeutic Efficacy 48 Lymphoma Leukemia 48 Myeloid 48 Revlimid 48 Chronic Renal Failure 48 Treatment Outcome 48 mCRC patients